Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.59 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.59 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.56 |
| ▸ | MPO | P05164 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29984623 | 1.00 | BRD4 (0.59) | BRD4ATAD2NR1H2MPOCHRM4 | |
| SCHEMBL31521005 | 0.92 | NR1H2 (0.62) | BRD4ATAD2NR1H2MPOCHRM4 | |
| SCHEMBL1098102 | 0.92 | NR1H2 (0.62) | BRD4ATAD2NR1H2MPOCHRM4 | |
| SCHEMBL6846584 | 0.90 | NR1H2 (0.56) | BRD4ATAD2NR1H2MPOKDM4E | |
| SCHEMBL1734404 | 0.85 | ESR2 (0.55) | BRD4ATAD2NR1H2MPOCHRM4 | |
| SCHEMBL15074680 | 0.85 | KDM4E (0.58) | BRD4NR1H2MPOCHRM4DRD2 | |
| SCHEMBL17795396 | 0.84 | BRD4 (0.45) | BRD4ATAD2NR1H2MPOCHRM4 | |
| SCHEMBL29631022 | 0.84 | ALDH1A1 (0.45) | BRD4NR1H2MPOCHRM4DRD2 | |
| SCHEMBL3576898 | 0.84 | ALDH1A1 (0.45) | BRD4NR1H2MPOCHRM4DRD2 | |
| SCHEMBL29507021 | 0.84 | BRD4 (0.45) | BRD4ATAD2NR1H2MPOCHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074904-A1 | NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-03-06 | — | — | US | disclosed |
| WO-2023091565-A1 | NSD2-TARGETED CHEMICAL DEGRADERS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023072026-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-05-04 | — | — | WO | disclosed |
| US-20230109104-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC (US) | 2023-04-06 | — | — | US | disclosed |
| US-11299493-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2022-04-12 | — | — | US | disclosed |
| EP-3564232-B1 | BMP-SIGNAL-INHIBITING COMPOUND | RIKEN (JP) | 2022-01-26 | — | — | EP | disclosed |
| WO-2021212039-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021212039-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-10-21 | — | — | WO | disclosed |
| US-20210154317-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | ARS Pharmaceuticals, Inc. | 2021-05-27 | — | — | US | disclosed |
| US-10954216-B2 | BMP-signal-inhibiting compound | RIKEN (JP) | 2021-03-23 | — | — | US | disclosed |
| EP-1974212-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | Vertex Pharmaceuticals Incorporated (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20080132540-A1 | NON-PEPTIDIC NPY Y2 RECEPTOR INHIBITORS | CARRUTHERS NICHOLAS I | 2008-06-05 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-7317025-B2 | Non-peptidic NPY Y2 receptor inhibitors | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, LLC (US) | 2008-01-08 | — | — | US | disclosed |
| WO-2007075946-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1773816-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| WO-2006002421-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050070534-A1 | Non-peptidic NPY Y2 receptor inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299493-B2 | Heterocyclic compounds and uses thereof | WEE1, WEE2, NME1 | BRD4 56/4885ATAD2 2507/4885NR1H2 4452/4885 |
| US-20230109104-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | BRD4 56/4885ATAD2 2507/4885NR1H2 4452/4885 |
| US-10954216-B2 | BMP-signal-inhibiting compound | BMP1, BMP2, BMP4 | BRD4 457/4885ATAD2 2424/4885NR1H2 1047/4885 |
| US-20250074904-A1 | NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF | NCOR2, NSD2, NCOR1 | BRD4 106/4885ATAD2 99/4885NR1H2 140/4885 |
| US-20080132540-A1 | NON-PEPTIDIC NPY Y2 RECEPTOR INHIBITORS | NPY2R, NPY1R, NPY5R | BRD4 2341/4885ATAD2 2981/4885NR1H2 1575/4885 |
| US-20210154317-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, FCGR3B, FCGR1A | BRD4 2804/4885ATAD2 4218/4885NR1H2 335/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | BRD4 1716/4885ATAD2 597/4885NR1H2 234/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | BRD4 2321/4885ATAD2 768/4885NR1H2 286/4885 |
| US-20050070534-A1 | Non-peptidic NPY Y2 receptor inhibitors | NPY2R, NPY1R, NPY5R | BRD4 2341/4885ATAD2 2981/4885NR1H2 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.